asthma-like

Methacholine Chloride (Acetyl-β-methylcholine chloride) is a quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma.

AZD8848 is a selective antedrug agonist of toll-like receptor 7 (TLR7). It is developed for the research of asthma and allergic rhinitis.

Bamaquimast (L 0042) is a proton pump inhibitor for the study of asthma-like immune system disorders and respiratory diseases.

Fenspiride hydrochloride (Decaspiride) , an oxazolidinone spiro compound, is a drug used in the therapy of certain respiratory diseases. It is approved for use in Russia for the therapy of chronic and acute inflammatory diseases of ENT organs and the respiratory tract (like sinusitis, tracheobronchitis, otitis, laryngitis, and rhinopharyngitis), and for maintenance therapy of asthma.

CU-T12-9 is a potent TLR1/2 agonist(EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay). It acts by activating the NFkB pathway, upregulating proinflammatory cytokines, and enhancing TLR1 and TLR2 dimerization.CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.

TLR7 agonist18 (Compound 21a) is a selective Toll-like receptor 7 (TLR7) agonist with an EC50 of 7.8 μM. It demonstrates no cytotoxicity in an HEK293 cell line co-transfected with the hTLR7 gene and can induce the secretion of several cytokines, including IL-1β, IL-12p70, IL-8, and TNF-α. This compound is useful in research related to vaccines, asthma, allergies, and cancer treatment.

c-Kit-IN-11 (Compound A7) is a c-Kit inhibitor with an IC50 of 76 nM against Mo7e cells. This compound is applicable for research in inflammatory conditions like asthma and malignant cancers.

LMD-902 is an analog of LMD-009 and acts as a CCR8 agonist with an EC50 of 15 nM. It exhibits excellent binding affinity, which is reliant on crucial residues such as PheVI:16. LMD-902 can be utilized in research for inflammatory conditions like bronchial asthma and central nervous system diseases such as multiple sclerosis.

L48H37 is a chemically stable analog of Curcumin. It exhibits potent inhibitory properties against myeloid differentiation protein 2 (MD2), acting as a specific inhibitor. Its mechanism involves inhibiting the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is primarily utilized in sepsis and lung injury research [1].

Methacholine bromide (Acetyl-β-methylcholine bromide) is a potent muscarinic-3 (M3) agonist that specifically acts on acetylcholine receptors located on smooth muscle, inducing bronchoconstriction and narrowing of the airways. Its high sensitivity in identifying bronchial hyperresponsiveness (BHR), a hallmark of asthma, makes it useful in the assessment of airway hyperresponsiveness (AHR) as a diagnostic tool for individuals exhibiting asthma-like symptoms with normal resting expiratory flow rates [1] [2] [3] [4].

ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor and a competitive inhibitor of NTPDase1 (CD39), NTPDase3, and NPP1, with K i values of 11, 18, and 12 μM respectively. It is used in research of diseases such as calcific aortic valve disease and asthma [1] [2].

Tirzepatide sodium is the sodium salt form of a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist peptide drug that enhances insulin secretion and improves glycemic control by simultaneously activating GIP and GLP-1 receptors. In research and clinical settings, Tirzepatide sodium has also demonstrated effects in reducing body weight and improving metabolic parameters, and is used in studies related to type 2 diabetes and metabolic disorders.

HYDAMTIQ, a PARP-1/2 inhibitor (IC 50 : 29-38 nM), exhibits a range of pharmacological effects including anticancer, anti-inflammatory, and ischemic protective properties. It effectively reduces pulmonary PARP activity and alleviates symptoms such as allergen-induced cough and dyspnea while also diminishing bronchial hyperresponsiveness to methacholine. Moreover, HYDAMTIQ shows potent tumor suppressor activity in various cancers such as ovarian, breast, prostate, pancreatic, and glioblastoma multiforme. Demonstrating in vivo efficacy, HYDAMTIQ has been tested in animal models for conditions like cerebral ischemia, asthma, and cancer [1].

ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. It is utilized in researching autoimmune diseases such as rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD), and other conditions including asthma.

AK006 is a humanized IgG1 monoclonal antibody agonist targeting sialic acid-binding immunoglobulin-like lectin 6 (Siglec-6). It effectively inhibits IgE-mediated activation of human mast cells. AK006 is applicable in the study of inflammatory diseases such as chronic urticaria (CU) and asthma.

TQC2938 is a humanized IgG2 monoclonal antibody inhibitor that targets stimulating factor-2 (ST2). It blocks the ST2/IL-33 signaling pathway, reducing downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and levels of eosinophils and other inflammatory cells. TQC2938 is applicable for research in inflammatory diseases like asthma.

Endothelin (16-21) is a selective ETB receptor agonist with an EC50 of 228 nM in guinea pig bronchial rings. It induces smooth muscle contraction and shows potential for research into respiratory conditions such as asthma, as well as cardiovascular diseases like hypertension.